What can GP data tell us about the treatment of onychomycosis in the UK?

Background: Treatment of onychomycosis is challenging, and there is much literature on optimal treatment strategies. In contrast, information on how onychomycosis is actually treated in primary care is scarce. Information on practice is important as it can reveal much, such as, to what extent national guidelines are followed and which population groups seek/receive treatment or do not do so. // Objectives: To describe the pattern of onychomycosis treatment in primary care in the UK, by patient's gender and age. // Methods: A population-based retrospective cross-sectional study was conducted. The Health Improvement Network (THIN) database was used to calculate incidence rates of onychomycosis in the years 2001–2017. The prescription of oral and topical anti-fungal drugs to patients with onychomycosis was reviewed. // Results: THIN data showed an onychomycosis incidence rate of about 50 per 100,000. More males than females (52% vs. 48%), and more people aged 50–59 years had received treatment for onychomycosis. Oral terbinafine was the most commonly prescribed drug, followed by topical amorolfine, although terbinafine was used more commonly by men and amorolfine by women. Patients with onychomycosis were also prescribed other antifungals, including itraconazole, griseofulvin, tioconazole, ketoconazole shampoo, fluconazole and clotrimazole. A greater proportion of women, compared to men, were prescribed fluconazole. // Conclusions: Onychomycosis treatment in primary care in the UK is broadly in concordance with national guidelines

Experimental quantum fingerprinting with weak coherent pulses

This work was supported in part by ID Quantique, CFI, OIT, NSERC RTI, the NSERC SPG FREQUENCY, the NSERC Discovery Program, the CRC Program, Connaught Innovation fund and Industry Canada. We thank A. Ignjatovic, Pedro Palacios-Avila, Z. Tang and Francisco de Zela for valuable discussions. Particularly, F. Xu and K. Wei thank V. Makarov for his hospitality during their visit to IQC. We acknowledge the support from the Mike and Ophelia Lazaridis Fellowship, the Office of Naval Research (ONR), the Air Force Office of Scientific Research (AFOSR), the National Natural Science Foundation of China (Grant No. 61178010), China Scholarship Council (No. 201406470051), the University of Hong Kong Physics Department Summer Overseas Research Program and the Science Faculty Overseas Research Fellowship, CONCYTEC-Peru, USEQIP, the IQC Summer URA, the NSERC Postdoctoral Fellowships Program and CryptoWorks21.Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica - Concyte

Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer

Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of this study was to demonstrate pharmacokinetics (PK) similarity of BEVZ92 to RMP, in combination in combination with FOLFOX or FOLFIRI, as first-line treatment in patients with mCRC (NCT02069704). Methods: PK analysis for multiple dose studies was conducted, ..